Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry representatives urge policy reforms, including energy access and expanded PLI schemes, to bolster competitiveness. Delayed GST refunds and liquidity issues further challenge smaller drug manufacturers, impacting their ability to compete globally and respond to disruptions.

Indian MSMEs are urging a policy overhaul to boost global competitiveness, citing challenges from geopolitical shifts and supply chain disruptions. Industry leaders emphasise the…

Indian chemical industry leaders are urging a policy overhaul to boost competitiveness ahead of World MSME Day 2026. They highlight the need for resilient supply chains, easier…

Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry representatives urge policy reforms, including…